Trinity Biotech (TRIB) said Tuesday it has secured $5.5 million in additional liquidity through amended agreements with Perceptive Advisors, including cash and payment-in-kind interest.

As part of the agreement, Trinity has granted Perceptive 1.5 million additional warrants to buy its American depositary shares and repriced its existing warrants to $0.80 per ADS, Trinity added.

A $5 million deferred payment tied to its acquisition of Waveform Technologies assets was also extended to November 2025, increasing its financial flexibility, Trinity Biotech said.

The liquidity will support the company's transformation plan, including its World Health Organization-approved transition to offshore manufacturing for TrinScreen HIV and Uni-Gold HIV, Trinity Biotech said.

Trinity Biotech were up more than 10% in recent premarket activity.